<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560024</url>
  </required_header>
  <id_info>
    <org_study_id>H-18016693</org_study_id>
    <nct_id>NCT03560024</nct_id>
  </id_info>
  <brief_title>The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers</brief_title>
  <official_title>The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by MRA on Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying Pituitary adenylate cyclase-activating peptide 27 (PACAP27) effects on extra- and
      intracerebral arteries assessed by MRA on healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PACAP neuropeptide, which belongs to the vasoactive intestinal polypeptide
      (VIP)/glucagon/secretin family. PACAP exists in two forms: Studying Pituitary adenylate
      cyclase-activating peptide 38 (PACAP38), which consists of 38 amino acids and PACAP27 which
      contains 27 amino acids at its N-terminus. PACAP38 is implicated in migraine pathophysiology
      however PACAP27 is not studied well. Therefore, the investigators will study PACAP27's effect
      on extra- and intracerebral arteries assessed by MRA on healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>18 healthy volunteers will receive PACAP27 or placebo. All Data will also be analyses blinded.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized, double-blind placebo-controlled design in healthy volunteers.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dilation of extra- and intracerebral arteries</measure>
    <time_frame>0-290 min</time_frame>
    <description>A single-slab 3D time-of-flight (3D TOF) MRA of extra- and intracranial arteries will be acquired as described in previous studies (Amin et al., 2013, 2014). MRA data will be analyzed by LKEB-MRA vessel wall analysis software program. We will measure the circumference of vessels in millimeter in five predefined time points (0, 20, 110, 200 and 290 min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Headache intensity (Visual analog scale 0-10), characteristics, location and migraine associated symptoms will be recorded in questionnaire at hospital (6 hours) and post hospital (18 hours). In hospital phase, headache questionnaire will be filled every 30 min and post hospital every hour.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Headache, Migraine</condition>
  <arm_group>
    <arm_group_label>PACAP27</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 healthy volunteers will receive placebo (Saline) over 20 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PACAP27</intervention_name>
    <description>PACAP27 is vasodilator of cerebral vessels</description>
    <arm_group_label>PACAP27</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Aged 18-50

          -  50-100 kg

        Exclusion Criteria:

          -  Tension type headache more than 5 dag /month

          -  Other primary headaches

          -  Daily medication except contraceptives

          -  Drug taken within 4 times the half-life for the specific drug except contraceptives

          -  Pregnant or lactating women

          -  Exposure to radiation within the last year

          -  Headache within the last 24 hours before start of trial

          -  Hypertension

          -  Hypotension

          -  Respiratory or cardiac disease

          -  Primary relatives with current or previous migraine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Hashmat Ghanizada</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

